登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600196 证券简称：复星医药公告编号：临2025-170 上海复星医药（集团）股份有限公司 第十届董事会第十四次会议（临时会议） 决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 上海复星医药（集团）股份有限公司（以下简称"本公司"）第十届董事会第十四次会议（临时会议）于 2025年11月4日召开，全体董事以通讯方式出席了会议。本次会议的召开符合《中华人民共和国公司 法》、其他有关法律法规和《上海复星医药（集团）股份有限公司章程》的规定。会议审议并达成如下 决议： 一、审议通过关于2025年A股股票期权激励计划首次授予相关事项的议案。 1、根据本公司2025年第一次临时股东会（以下简称"股东会"）已审议通过之《上海复星医药（集团） 股份有限公司2025年A股股票期权激励计划》（以下简称"2025年A股期权计划"）及相关授权，鉴于该 计划下首次授予拟激励对象中的6名已不在本集团（即本公司及控股子公司/单位，下同）任职、不再属 于该计划的激励对象范围，董事会同 ...

Core Viewpoint - Junshi Biosciences (01877) announced the approval of the 2025 H-share and A-share stock option incentive plans by the board of directors, which require shareholder approval due to the issuance of new shares [1] Group 1: Stock Option Incentive Plans - The board has approved the proposal to adopt the 2025 H-share stock option incentive plan and the 2025 A-share stock option incentive plan [1] - The 2025 H-share stock option incentive plan includes the granting of 13.21 million H-share stock options to seven executive directors and three other employee participants [1] - The 2025 A-share stock option incentive plan proposes granting 8 million A-share stock options to Mr. Xiong, contingent upon the adoption of the respective plans [1]

Group 1 - Junshi Biosciences (688180.SH) announced a stock option incentive plan for 2025, proposing to grant a total of 26.175871 million stock options, which accounts for approximately 2.55% of the company's total share capital at the time of the announcement [1] - The initial grant of stock options is 25.36 million, representing about 2.47% of the company's total share capital at the time of the announcement, and 96.88% of the total options to be granted [1] - A reserve of 815871 stock options is planned, which accounts for approximately 0.08% of the company's total share capital at the time of the announcement, making up 3.12% of the total options to be granted [1]

Core Viewpoint - The legal opinion letter from Shanghai Chengming Zhenzheng Law Firm confirms that SF Holding Co., Ltd. has complied with necessary legal procedures for adjusting the exercise price of its stock options under the 2022 A-share stock option incentive plan, reducing the exercise price from RMB 40.199 per share to RMB 39.761 per share [1][10]. Summary by Sections Adjustment Details - The adjustment of the exercise price is based on the company's 2024 A-share dividend distribution plan, which involves a cash dividend of RMB 4.40 per 10 shares, resulting in a new exercise price calculation [4][5]. - The formula for adjusting the exercise price is P = P0 - V, where P0 is the original exercise price and V is the dividend per share [5]. Approval and Authorization - The company has obtained necessary approvals and authorizations for the adjustment, including independent opinions from independent directors and compliance with relevant laws and regulations [6][10]. - The adjustment process involved the avoidance of conflicts of interest by related directors during the voting process [6][10]. Legal Compliance - The law firm asserts that the adjustment complies with the Company Law, Securities Law, and relevant management regulations, ensuring that the interests of the company and its shareholders are not harmed [7][10]. - The legal opinion emphasizes that the company must fulfill its information disclosure obligations as per legal requirements following the adjustment [10].

Group 1 - The core point of the article is that Fosun Pharma (600196.SH) announced a stock option incentive plan for 2025, which allows for the granting of up to 5,726,100 A-share options [1] - The total number of A-shares corresponding to the options is also 5,726,100, representing approximately 0.2144% of the company's total shares and 0.2729% of the total A-shares excluding treasury shares [1]

Core Points - The company has proposed a stock option incentive plan for 2025, aiming to enhance corporate governance and retain talent [9][10][12] - The total number of stock options to be granted is capped at 5,726,100, representing approximately 0.2144% of the company's total shares [14][15] - The plan includes an initial grant of 4,580,900 options (80% of the total) and a reserved grant of 1,145,200 options (20% of the total) [15][24] Summary by Sections Purpose of the Plan - The plan aims to align the interests of shareholders, the company, and its core team, ensuring long-term development and motivation for key personnel [9][10] Management Structure - The shareholders' meeting is the highest authority for approving the plan, while the board of directors is responsible for its execution [10][11] Incentive Recipients - The plan targets executive directors, employee directors, senior management, and other key employees, with a maximum of 201 initial recipients [12][13] Source and Quantity of Shares - The shares for the stock options will come from shares repurchased from the secondary market, with specific limits on the total number of shares that can be granted [14][15] Grant and Exercise Conditions - The exercise price for the initial grant is set at 27.93 yuan per share, based on the average trading price prior to the announcement [19][20] - The plan stipulates performance-based conditions for exercising options, including group-level financial metrics [21][24] Lock-up Regulations - There are restrictions on the transfer of shares by directors and senior management during their tenure and for a period after leaving the company [19][24]

Core Viewpoint - Shanghai Fosun Pharmaceutical Group Co., Ltd. has approved the initial grant list for the 2025 A-share stock option incentive plan during the seventh meeting of its tenth board of directors [1] Group 1 - The company has outlined the names and positions of the proposed incentive recipients for the stock option plan [1] - The decision was made on August 22, 2025, indicating a strategic move to motivate and retain key personnel within the organization [1]